Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Acquired initiating mutations in early hematopoietic cells of CLL patients.

Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, Diop M, Scourzic L, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Kikushige Y, Davi F, Lambert J, Gautheret D, Merle-Béral H, Sutton L, Dessen P, Solary E, Akashi K, Vainchenker W, Mercher T, Droin N, Ogawa S, Nguyen-Khac F, Bernard OA.

Cancer Discov. 2014 Sep;4(9):1088-101. doi: 10.1158/2159-8290.CD-14-0104.

2.

Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.

Maura F, Cutrona G, Mosca L, Matis S, Lionetti M, Fabris S, Agnelli L, Colombo M, Massucco C, Ferracin M, Zagatti B, Reverberi D, Gentile M, Recchia AG, Bossio S, Rossi D, Gaidano G, Molica S, Cortelezzi A, Di Raimondo F, Negrini M, Tassone P, Morabito F, Ferrarini M, Neri A.

Leuk Lymphoma. 2015;56(11):3150-8. doi: 10.3109/10428194.2015.1028051.

PMID:
25860243
3.

Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.

Xia Y, Fan L, Wang L, Gale RP, Wang M, Tian T, Wu W, Yu L, Chen YY, Xu W, Li JY.

Oncotarget. 2015 Mar 10;6(7):5426-34.

4.

SF3B1 mutations in chronic lymphocytic leukemia.

Wan Y, Wu CJ.

Blood. 2013 Jun 6;121(23):4627-34. doi: 10.1182/blood-2013-02-427641. Review.

5.

Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, Rossi FM, Monti S, Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del Poeta G, Gaidano G, Gattei V.

Blood. 2013 Jun 13;121(24):4902-5. doi: 10.1182/blood-2013-02-486209.

6.

Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.

Morabito F, Mosca L, Cutrona G, Agnelli L, Tuana G, Ferracin M, Zagatti B, Lionetti M, Fabris S, Maura F, Matis S, Gentile M, Vigna E, Colombo M, Massucco C, Recchia AG, Bossio S, De Stefano L, Ilariucci F, Musolino C, Molica S, Di Raimondo F, Cortelezzi A, Tassone P, Negrini M, Monti S, Rossi D, Gaidano G, Ferrarini M, Neri A.

Clin Cancer Res. 2013 Nov 1;19(21):5890-900. doi: 10.1158/1078-0432.CCR-13-0622.

7.

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Foà R, Dalla-Favera R, Gaidano G.

Blood. 2011 Dec 22;118(26):6904-8. doi: 10.1182/blood-2011-08-373159.

8.

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.

Quesada V, Conde L, Villamor N, Ordóñez GR, Jares P, Bassaganyas L, Ramsay AJ, Beà S, Pinyol M, Martínez-Trillos A, López-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, Delgado J, Giné E, Hernández JM, González-Díaz M, Puente DA, Velasco G, Freije JM, Tubío JM, Royo R, Gelpí JL, Orozco M, Pisano DG, Zamora J, Vázquez M, Valencia A, Himmelbauer H, Bayés M, Heath S, Gut M, Gut I, Estivill X, López-Guillermo A, Puente XS, Campo E, López-Otín C.

Nat Genet. 2011 Dec 11;44(1):47-52. doi: 10.1038/ng.1032.

PMID:
22158541
9.

Tracing the roots of cancer evolution.

Jiang Y, Elemento O.

Cancer Discov. 2014 Sep;4(9):995-7. doi: 10.1158/2159-8290.CD-14-0743.

10.

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R; European Research Initiative on CLL (ERIC)..

Leukemia. 2015 Feb;29(2):329-36. doi: 10.1038/leu.2014.196.

PMID:
24943832
11.

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.

Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S.

Blood. 2013 Apr 18;121(16):3284-8. doi: 10.1182/blood-2012-11-469627.

12.

Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.

Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM.

Cancer Genet. 2013 Mar;206(3):49-62. doi: 10.1016/j.cancergen.2013.01.003. Review.

PMID:
23531595
13.

The impact of SF3B1 mutations in CLL on the DNA-damage response.

Te Raa GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MH, Kater AP, Eldering E.

Leukemia. 2015 May;29(5):1133-42. doi: 10.1038/leu.2014.318.

PMID:
25371178
14.

Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.

Strefford JC, Sutton LA, Baliakas P, Agathangelidis A, Malčíková J, Plevova K, Scarfó L, Davis Z, Stalika E, Cortese D, Cahill N, Pedersen LB, di Celle PF, Tzenou T, Geisler C, Panagiotidis P, Langerak AW, Chiorazzi N, Pospisilova S, Oscier D, Davi F, Belessi C, Mansouri L, Ghia P, Stamatopoulos K, Rosenquist R.

Leukemia. 2013 Nov;27(11):2196-9. doi: 10.1038/leu.2013.98.

PMID:
23558524
15.

Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.

Ouillette P, Saiya-Cork K, Seymour E, Li C, Shedden K, Malek SN.

Clin Cancer Res. 2013 Jun 1;19(11):2893-904. doi: 10.1158/1078-0432.CCR-13-0138.

16.

New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.

Filip AA.

Leuk Lymphoma. 2013 Sep;54(9):1876-81. doi: 10.3109/10428194.2013.769049. Review.

PMID:
23343182
17.

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NC, Catovsky D, Strefford JC.

Blood. 2013 Jan 17;121(3):468-75. doi: 10.1182/blood-2012-05-429282.

18.

Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.

Del Giudice I, Chiaretti S, Santangelo S, Tavolaro S, Peragine N, Marinelli M, Ilari C, Raponi S, Messina M, Nanni M, Mauro FR, Piciocchi A, Bontempi K, Rossi D, Gaidano G, Guarini A, Foà R.

Am J Hematol. 2014 Jan;89(1):74-82.

19.

Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.

Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Famà R, Cresta S, Bruscaggin A, Laurenti L, Martini M, Musto P, Forconi F, Marasca R, Larocca LM, Foà R, Gaidano G.

Br J Haematol. 2012 Aug;158(3):426-9. doi: 10.1111/j.1365-2141.2012.09155.x. No abstract available.

PMID:
22571487
20.

NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.

Chiaretti S, Marinelli M, Del Giudice I, Bonina S, Piciocchi A, Messina M, Vignetti M, Rossi D, Di Maio V, Mauro FR, Guarini A, Gaidano G, Foà R.

Leuk Lymphoma. 2014 Dec;55(12):2785-92. doi: 10.3109/10428194.2014.898760.

PMID:
24597984
Items per page

Supplemental Content

Support Center